胃肠道中口服药物的损失。
Loss of orally administered drugs in GI tract.
机构信息
Dept. of Pharmaceutics, Govt. College of Pharmacy, Karad (MS), India.
出版信息
Saudi Pharm J. 2012 Oct;20(4):331-44. doi: 10.1016/j.jsps.2012.03.005. Epub 2012 Apr 20.
Abstract
The aim of this review is to provide a broad perspective on intestinal absorption and the impact of intestinal first-pass metabolism on both clearance and drug-drug interaction prediction along with its historical perspectives. The review also considers abilities to bridge the gap between the increasing amount of intestinal in vitro data and the importance of intestinal first-pass metabolism in vivo. The significance of efflux transporters on the intestinal absorption is also discussed.
摘要
本次综述旨在提供一个广泛的视角，讨论肠道吸收以及肠道首过代谢对清除率和药物相互作用预测的影响，同时回顾其历史发展。本文还考虑了如何弥合肠道体外数据量不断增加与体内肠道首过代谢重要性之间的差距。本文还讨论了外排转运体对肠道吸收的重要性。
相似文献
1
Loss of orally administered drugs in GI tract.胃肠道中口服药物的损失。
Saudi Pharm J. 2012 Oct;20(4):331-44. doi: 10.1016/j.jsps.2012.03.005. Epub 2012 Apr 20.
2
Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.代谢与转运在决定口服药物吸收和肠道壁代谢中的相互作用：应用“先进的溶解、吸收、代谢（ADAM）”模型进行的模拟评估。
Curr Drug Metab. 2010 Nov;11(9):716-29. doi: 10.2174/138920010794328913.
3
Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum.利用包含新鲜分离人空肠的尤斯灌流室系统对人肠道药物转运进行表征。
Drug Metab Dispos. 2021 Jan;49(1):84-93. doi: 10.1124/dmd.120.000138. Epub 2020 Oct 21.
4
Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.酶催化的首过肝肠药物提取过程。
Adv Drug Deliv Rev. 1997 Sep 15;27(2-3):99-127. doi: 10.1016/s0169-409x(97)00039-2.
5
In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.基于 UK-343,664 的非线性吸收动力学的计算建模：一种 P-糖蛋白和 CYP3A4 底物。
Mol Pharm. 2012 Mar 5;9(3):492-504. doi: 10.1021/mp200275j. Epub 2012 Feb 2.
6
Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.肠道首过代谢的最大抑制作为肠道对CYP3A4清除药物药物相互作用贡献的实用指标。
Curr Drug Metab. 2007 Oct;8(7):685-93. doi: 10.2174/138920007782109805.
7
Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.沿人体小肠的 P-糖蛋白（ABCB1）、BCRP（ABCG2）和 CYP3A4 量的变化对预测肠道首过的 PBPK 模型的影响。
Mol Pharm. 2010 Oct 4;7(5):1596-607. doi: 10.1021/mp100015x. Epub 2010 Aug 4.
8
Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.五种细胞色素P450酶的肠道和肝脏代谢活性：对首过代谢预测的影响
J Pharmacol Exp Ther. 2006 Sep;318(3):1220-9. doi: 10.1124/jpet.106.106013. Epub 2006 Jun 8.
9
Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.肠首过代谢由细胞色素 p450 而不是 p-糖蛋白是安普那韦吸收的主要屏障。
Drug Metab Dispos. 2013 Sep;41(9):1695-702. doi: 10.1124/dmd.113.052191. Epub 2013 Jul 2.
10
Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension.P-糖蛋白、多药耐药相关蛋白2（MRP2）和细胞色素P450 3A4（CYP3A4）的过表达会损害门静脉高压大鼠中奥曲肽的肠道吸收。
BMC Gastroenterol. 2021 Jan 6;21(1):2. doi: 10.1186/s12876-020-01532-4.
引用本文的文献
1
Surface Defects and Crystal Growth of Apremilast Benzoic Acid Cocrystals.阿普斯特苯甲酸共晶体的表面缺陷与晶体生长
Org Process Res Dev. 2025 Mar 19;29(4):1067-1075. doi: 10.1021/acs.oprd.4c00480. eCollection 2025 Apr 18.
2
Evaluation of Biologics ACE2/Ang(1-7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies.评估用于美国食品药品监督管理局（FDA）批准的封装在植物细胞中的生物制剂ACE2/血管紧张素（1-7）：安全性和毒理学研究。
Pharmaceutics. 2024 Dec 25;17(1):12. doi: 10.3390/pharmaceutics17010012.
3
Oral Administration of [F]MC225 for Quantification of P-glycoprotein Function: A Feasibility Study.口服[F]MC225用于定量P-糖蛋白功能：一项可行性研究。
Mol Imaging Biol. 2025 Feb;27(1):89-98. doi: 10.1007/s11307-024-01975-1. Epub 2025 Jan 14.
4
A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden.一种基于酵母的口服疗法可递送免疫检查点抑制剂以减轻肠道肿瘤负担。
Cell Chem Biol. 2025 Jan 16;32(1):98-110.e7. doi: 10.1016/j.chembiol.2024.10.013. Epub 2024 Nov 20.
5
"Enhancing Oral Drug Absorption: Overcoming Physiological and Pharmaceutical Barriers for Improved Bioavailability"."增强口服药物吸收：克服生理和药物障碍以提高生物利用度"。
AAPS PharmSciTech. 2024 Oct 1;25(7):228. doi: 10.1208/s12249-024-02940-5.
6
Layer-by-Layer Nanoparticle Assembly for Biomedicine: Mechanisms, Technologies, and Advancement via Acoustofluidics.用于生物医学的逐层纳米颗粒组装：机制、技术及通过声流体技术取得的进展
ACS Appl Nano Mater. 2024 Jul 16;7(14):15874-15902. doi: 10.1021/acsanm.4c02463. eCollection 2024 Jul 26.
7
Targeted Therapy with Cisplatin-Loaded Calcium Citrate Nanoparticles Conjugated with Epidermal Growth Factor for Lung Cancer Treatment.用与表皮生长因子共轭的载顺铂柠檬酸钙纳米颗粒进行肺癌靶向治疗。
ACS Omega. 2024 Jun 9;9(24):25668-25677. doi: 10.1021/acsomega.3c08969. eCollection 2024 Jun 18.
8
The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs.蛋白类和肽类药物的现行与有前景的口服递药方法。
Int J Mol Sci. 2024 Jan 9;25(2):815. doi: 10.3390/ijms25020815.
9
Potentials of ionic liquids to overcome physical and biological barriers.离子液体克服物理和生物屏障的潜力。
Adv Drug Deliv Rev. 2024 Jan;204:115157. doi: 10.1016/j.addr.2023.115157. Epub 2023 Dec 15.
10
leaf extract enhances host resistance to infection in mice by regulating host immune response and disrupting the activity of parasite superoxide dismutase enzyme.叶提取物通过调节宿主免疫反应和破坏寄生虫超氧化物歧化酶的活性来增强小鼠对感染的抵抗力。
Front Microbiol. 2023 Oct 25;14:1275365. doi: 10.3389/fmicb.2023.1275365. eCollection 2023.
本文引用的文献
1
P-glycoprotein function and expression during obstructive cholestasis in rats.大鼠梗阻性胆汁淤积期间P-糖蛋白的功能与表达
Eur J Gastroenterol Hepatol. 2008 May;20(5):404-12. doi: 10.1097/MEG.0b013e3282f471bf.
2
P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity.两亲性二嵌段共聚物对P-糖蛋白外排的抑制作用：共聚物浓度与底物疏水性之间的关系。
Mol Pharm. 2008 Jul-Aug;5(4):643-53. doi: 10.1021/mp7001347. Epub 2008 Apr 2.
3
Strategies to in vitro assessment of major human CYP enzyme activities by using liquid chromatography tandem mass spectrometry.利用液相色谱串联质谱法对主要人细胞色素P450酶活性进行体外评估的策略。
Curr Drug Metab. 2008 Jan;9(1):12-9. doi: 10.2174/138920008783331112.
4
Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.二十二碳六烯酸（DHA）对咪达唑仑肠道代谢的抑制作用：大鼠的体外和体内研究
Int J Pharm. 2008 Mar 3;351(1-2):133-43. doi: 10.1016/j.ijpharm.2007.09.037. Epub 2007 Oct 5.
5
Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam.托非索泮抑制CYP3A4底物咪达唑仑的药代动力学。
Eur J Clin Pharmacol. 2008 Jan;64(1):93-4. doi: 10.1007/s00228-007-0397-y. Epub 2007 Nov 8.
6
Intestinal first-pass metabolism: bridging the gap between in vitro and in vivo.肠道首过代谢：弥合体外与体内之间的差距
Curr Drug Metab. 2007 Oct;8(7):643-4. doi: 10.2174/138920007782109779.
7
Sulfotransferase forms expressed in human intestinal Caco-2 and TC7 cells at varying stages of differentiation and role in benzo[a]pyrene metabolism.磺基转移酶在人肠道Caco-2和TC7细胞分化不同阶段的表达及其在苯并[a]芘代谢中的作用
Drug Metab Dispos. 2008 Feb;36(2):276-83. doi: 10.1124/dmd.107.018036. Epub 2007 Oct 29.
8
Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.口服泊沙康唑对环孢素和他克莫司药代动力学的影响。
Pharmacotherapy. 2007 Jun;27(6):825-34. doi: 10.1592/phco.27.6.825.
9
Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.口服酮康唑对食蟹猴体内咪达唑仑和非索非那定肠道首过效应的影响。
Drug Metab Dispos. 2007 Mar;35(3):410-8. doi: 10.1124/dmd.106.011288. Epub 2006 Dec 1.
10
Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.姜黄素诱导的P-糖蛋白和CYP3A表达变化对大鼠口服塞利洛尔和咪达唑仑药代动力学的影响。
Drug Metab Dispos. 2007 Jan;35(1):110-5. doi: 10.1124/dmd.106.011072. Epub 2006 Oct 18.
Zotero 插件